You searched for Gout - Page 50 of 96

Abstract Number: 250 • 2014 ACR/ARHP Annual Meeting
Early Gout Pain Response at 28 Hours Predicts Response at 5 Days on Both Patient Pain and Physician Global Assessment
Paul M. Peloso¹, Ted R. Mikuls², Brian W. Coburn³, H. Ralph Schumacher Jr.⁴, Davis F. Gates¹, Zoran Popmihajlov¹, Walter L. Straus¹ and R. Andrew Moore⁵, ¹Merck & Co., Inc., Whitehouse Station, NJ, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³Omaha VA and University of Nebraska Medical Center, Omaha, NE, USA, Omaha, NE, ⁴Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁵University of Oxford, Nuffield Division of Anaesthetics, Oxford, England
Background/Purpose This post-hoc analysis from a randomized trial1in acute gout asked whether early pain responses predict subsequent pain and investigator global responses. Methods Patient assessment…
Abstract Number: 182 • 2014 ACR/ARHP Annual Meeting
Effect of Urate-Lowering Therapy on Radiographic Changes in Gout Patients
Seulkee Lee¹, Inyoung Kim¹, Hyemin Jeong¹, Jiwon Hwang¹, Hyungjin Kim¹, Jaejoon Lee², Hoon-Suk Cha¹ and Eun-mi Koh², ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Division of Rheumatology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose The aim of this study was to investigate the radiographic changes in patients with gout in association with the control of serum uric acid…
Abstract Number: 181 • 2014 ACR/ARHP Annual Meeting
Adherence to Treatment Recommendations of Gout: A Patient Survey in China
Feng Sheng, Xuejun Zeng and Weigang Fang, Medicine, Peking Union Medical College Hospital, Beijing, China
Background/Purpose The prevalence of gout appeared to be increasing in China as its economy developed rapidly in the past three decades. Though efficacious and affordable…
Abstract Number: 179 • 2014 ACR/ARHP Annual Meeting
Effect of Allopurinol on All-Cause Mortality in Adults with Incident Gout: Propensity Score Matched Landmark Analysis
Chang-Fu Kuo^1,2, Matthew J. Grainge³, Christian Mallen⁴, Weiya Zhang¹ and Michael Doherty⁵, ¹Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, ²Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taipei, Taiwan, ³Division of Epidemiology and Public Health, School of Community Health Sciences,, University of Nottingham, Nottingham, United Kingdom, ⁴Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom, ⁵Division of Rheumatology, Orthopedics and Dermatology, University of Nottingham, Nottingham, United Kingdom
Background/Purpose Although current guidelines recommend allopurinol as a first-line urate-lowering treatment for gout patients, whether the balance of potential benefits and risks can translate to…
Abstract Number: 177 • 2014 ACR/ARHP Annual Meeting
Increase in Thyroid Stimulating Hormone (TSH) Levels in Patients with Gout Treated with Inhibitors of Xanthine-Oxido-Reductase
Fernando Perez-Ruiz^1,2, Ana M. Herrero-Beites^1,3, M. Angeles Aniel-Quiroga⁴ and Sandra P Chinchilla⁵, ¹BioCruces Health Research Institute, Baracaldo, Spain, ²Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain, ³Physical Medicine Division, Hospital de Gorliz, Gorliz, Spain, ⁴Biochemistry, Hospital Universitario Cruces, Baracaldo, Spain, ⁵Rheumatology, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: Increase in thyroid stimulating hormone (TSH) levels over upper normal limit has been reported in a small percentage of patients treated with febuxostat, but…
Abstract Number: 170 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Skin Reactions with Gout Medications: An Analysis of VA Databases
Jasvinder A. Singh¹, Shuo Yang² and Jeff Foster³, ¹University of Alabama and VA Medical Center, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Dermatologic side effects to use of gout treatments are concerning to patients. The goal of the study was to assess the risk of occurrence…
Abstract Number: 169 • 2014 ACR/ARHP Annual Meeting
Is Gout a Coronary Heart Disease Risk Equivalent, Similar to Diabetes?
Jasvinder A. Singh¹, Rekha Ramachandaran², Jie Zhang³, Fenglong Xie⁴, Shuo Yang⁵, Huifeng Yun⁶ and Jeffrey R. Curtis², ¹Department of Medicine, University of Alabama, Tuscaloosa, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Ryals Soph Bldg., Rm. 517b, Univ. of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁵Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL
Background/Purpose: Diabetes is a well-recognized risk factor for heart disease, increasing the risk of heart disease by 2-3 fold in many studies. Recent ACC/AHA lipid…
Abstract Number: 168 • 2014 ACR/ARHP Annual Meeting
Positive Association Between Tomato Consumption and Serum Urate: Investigating an Anecdotal Trigger of Gout Flares
Tony R. Merriman¹, Nicola Dalbeth², Peter B. B. Jones³, Lisa K. Stamp⁴, Murray Cadzow⁵, Ruth Topless¹ and Tanya Flynn⁵, ¹Department of Biochemistry, University of Otago, Dunedin, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Medicine, Waikato Clinical School, Waikato Hospital, Hamilton, New Zealand, ⁴Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ⁵University of Otago, Dunedin, New Zealand
Background/Purpose: Gout is characterised by intermittent flares of inflammation in response to monosodium urate crystals in the joints. Gout flares can be triggered by dietary…
Abstract Number: 166 • 2014 ACR/ARHP Annual Meeting
Risk Factors for Gout Attack Recurrence during Urate-Lowering Allopurinol Treatment
Myeong Jae Yoon¹, Ji Ae Yang², Sang Hyun Joo¹, Sang Jin Lee¹, Jin Young Moon¹, Hyun Mi Kwon¹, Dong Jin Ko¹, Yeong Wook Song¹ and Eun Bong Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Background/Purpose Gout is a recurrent inflammatory arthritis caused by crystal deposition of monosodium urate, which can be prevented urate-lowering agents such as allopurinol. However, gout…
Abstract Number: 165 • 2014 ACR/ARHP Annual Meeting
Prevalence of Gout in the Adult Population of France in 2013
Thomas Bardin¹, Pierre Clerson², Stéphane Bouée³, Gerard H. Chales⁴, Michael Doherty⁵, René-Marc Flipo⁶, Charles Lambert⁷, Frédéric Lioté⁸, Thierry Poireaud⁹, Thierry Schaeverbeke¹⁰ and Pascal Richette¹¹, ¹Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, ²Orgametrie, Roubaix, France, ³Cemka, Bourg la Reine, France, ⁴Dept of Rheumatology, CHR - Hopital Sud, Rennes, France, ⁵Division of Rheumatology, Orthopedics and Dermatology, University of Nottingham, Nottingham, United Kingdom, ⁶rheumatology, Rene Salengro hospital, Lille, France, ⁷Ipsen, Boulogne Billancourt, France, ⁸Hôpital Lariboisière & University Paris Diderot, Paris, France, ⁹Menarini, Rungis, France, ¹⁰Rheumatology, Bordeaux University Hospital, Bordeaux, France, ¹¹INSERM 1132, Université Paris-Diderot, Hôpital Lariboisière, Paris, France
Background/Purpose The prevalence of gout has been studied in several Western countries by various methods to approach gout diagnosis, and has been estimated to vary…
Abstract Number: 164 • 2014 ACR/ARHP Annual Meeting
Gouty Patients with History of Adverse Reaction to Allopurinol Are Not at Higher Risk of Reaction to Febuxostat
Thomas Bardin¹, René-Marc Flipo², Pascal Richette³ and Pierre Clerson⁴, ¹Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, ²rheumatology, Rene Salengro hospital, Lille, France, ³INSERM 1132, Université Paris-Diderot, Hôpital Lariboisière, Paris, France, ⁴Orgametrie, Roubaix, France
Background/Purpose Allopurinol is the standard drug for urate-lowering management of gout. Allopurinol is safe in most patients. The most frequent side effects are minor cutaneous…
Abstract Number: 162 • 2014 ACR/ARHP Annual Meeting
Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises
Hugh de Lautour¹, Nicola Dalbeth² and William Taylor³, ¹Rheumatology, Auckland District Health Broad, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Rehabilitation Teaching & Research Unit, University of Otago, Wellington, New Zealand
Background/Purpose There are currently no agreed remission criteria for gout. The aim of this study was to establish consensus for elements of potential remission criteria…
Abstract Number: 161 • 2014 ACR/ARHP Annual Meeting
Ultrasonographic Measurement of Renal and Carotid Artery Resistive Indices and Diastolic Function of the Heart in Gout Patients
Rada Gancheva¹, Atanas Kundurdjiev², Mariana Ivanova¹, Todor Kundurzhiev³, Rasho Rashkov¹ and Zlatimir Kolarov¹, ¹University Hospital "St. Iv. Rilski", Clinic of Rheumatology, Sofia, Bulgaria, ²University Hospital "Alexandrovska", Clinic of Nephrology, Sofia, Bulgaria, ³Medical University, Faculty of Public Health, Sofia, Bulgaria
Background/Purpose Our aim was to assess the impact of gout on kidneys, diastolic function of the heart and carotid arteries. We examined ultrasonographic parameters that…
Abstract Number: 160 • 2014 ACR/ARHP Annual Meeting
All Men with Gout Should be Screened for Erectile Dysfunction
Naomi Schlesinger¹, Diane C. Radvanski² and John Kostis³, ¹Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, ²Department of Medicine, Division of Rheumatology, Robert Wood Johnson Medical School, New Brunswick, NJ, ³Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose Erectile dysfunction (ED) is common in the general population. The likelihood of ED increases progressively with age; however, it is not an inevitable consequence…
Abstract Number: 159 • 2014 ACR/ARHP Annual Meeting
Canakinumab in Frequently Flaring Gouty Arthritis Patients, Contraindicated, Intolerant or Unresponsive to non-Steriodal Anti-Inflammatory drugs and/or Colchicine: Safety and Efficacy Results from Long Term Follow-up
Naomi Schlesinger¹, Rieke Alten², Thomas Bardin³, H. Ralph Schumacher Jr.⁴, Mark Bloch⁵, Karine Lheritier⁶, Dominik Richard⁶, Andrea Stancati⁷ and Alexander So⁸, ¹Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, ²Charité University Medicine, Berlin, Germany, ³Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, ⁴University of Pennsylvania VA Medical Center, Philadelphia, PA, ⁵Holdsworth House Medical Practice, Sydney, Australia, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Campus Forum 1, Novartis Pharma AG, Basel, Switzerland, ⁸Rheumatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland
Background/Purpose Frequently flaring acute gouty arthritis (GA) patients (pts), in whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffective, need effective alternative treatments.1 Canakinumab…

Early Gout Pain Response at 28 Hours Predicts Response at 5 Days on Both Patient Pain and Physician Global Assessment

Effect of Urate-Lowering Therapy on Radiographic Changes in Gout Patients

Adherence to Treatment Recommendations of Gout: A Patient Survey in China

Effect of Allopurinol on All-Cause Mortality in Adults with Incident Gout: Propensity Score Matched Landmark Analysis

Increase in Thyroid Stimulating Hormone (TSH) Levels in Patients with Gout Treated with Inhibitors of Xanthine-Oxido-Reductase

Increased Risk of Skin Reactions with Gout Medications: An Analysis of VA Databases

Is Gout a Coronary Heart Disease Risk Equivalent, Similar to Diabetes?

Positive Association Between Tomato Consumption and Serum Urate: Investigating an Anecdotal Trigger of Gout Flares

Risk Factors for Gout Attack Recurrence during Urate-Lowering Allopurinol Treatment

Prevalence of Gout in the Adult Population of France in 2013

Gouty Patients with History of Adverse Reaction to Allopurinol Are Not at Higher Risk of Reaction to Febuxostat

Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises

Ultrasonographic Measurement of Renal and Carotid Artery Resistive Indices and Diastolic Function of the Heart in Gout Patients

All Men with Gout Should be Screened for Erectile Dysfunction

Canakinumab in Frequently Flaring Gouty Arthritis Patients, Contraindicated, Intolerant or Unresponsive to non-Steriodal Anti-Inflammatory drugs and/or Colchicine: Safety and Efficacy Results from Long Term Follow-up

Simple Search Results